Department of Hygiene, Epidemiology and Medical Statistics, University of Athens Medical School, 75 M. Asias Street, Goudi GR-115 27, Greece.
Br J Cancer. 2013 Jan 15;108(1):199-204. doi: 10.1038/bjc.2012.493. Epub 2012 Nov 20.
Limited information exists about the endocrine milieu of benign breast disease (BBD), a documented breast cancer risk factor. We compared blood levels of estrogens, testosterone and insulin-like growth factor-1 (IGF-1) between BBD patients by histological type and women without breast pathology.
We studied 578 BBD patients and 178 healthy women in Athens, Greece, who provided blood samples, and completed interviewer-administered questionnaires.
Of the BBD patients, 254 had non-proliferative disease, 268 proliferative disease without atypia and 56 atypical hyperplasia. Comparing BBD patients with healthy women, the per cent differences (and 95% confidence intervals) for blood hormones, among pre-menopausal and peri/post-menopausal women, respectively, were: 22.4% (-4.0%, 56.1%) and 32.0% (5.6%, 65.1%) for estradiol; 26.2% (10.1%, 44.8%) and 30.9% (16.8%, 46.6%) for estrone; 19.5% (3.1%, 38.4%) and 16.5% (-5.0%, 42.9%) for testosterone; and -5.2% (-13.8%, 4.4%) and -12.1% (-19.8%, -3.6%) for IGF-1. Steroid hormones tended to be higher in proliferative compared with non-proliferative BBD.
Circulating steroid hormones tend to be higher among women with BBD than women with no breast pathology and higher in proliferative than non-proliferative disease; these patterns are more evident among peri/post-menopausal women. In peri/post-menopausal women IGF-1 was lower among women with BBD compared with healthy women.
良性乳腺疾病(BBD)是一种已被证实的乳腺癌风险因素,但其内分泌环境的相关信息十分有限。我们比较了不同组织学类型的 BBD 患者与无乳腺病变女性的雌激素、睾酮和胰岛素样生长因子-1(IGF-1)的血液水平。
我们在希腊雅典研究了 578 名 BBD 患者和 178 名健康女性,她们提供了血液样本并完成了访谈式问卷调查。
在 BBD 患者中,254 名患有非增生性疾病,268 名患有非典型增生前增生性疾病,56 名患有不典型增生。与健康女性相比,在绝经前和绝经后女性中,BBD 患者的血液激素差异百分比(95%置信区间)分别为:雌二醇分别为 22.4%(-4.0%,56.1%)和 32.0%(5.6%,65.1%);雌酮分别为 26.2%(10.1%,44.8%)和 30.9%(16.8%,46.6%);睾酮分别为 19.5%(3.1%,38.4%)和 16.5%(-5.0%,42.9%);IGF-1 分别为-5.2%(-13.8%,4.4%)和-12.1%(-19.8%,-3.6%)。与非增生性 BBD 相比,增生性 BBD 患者的甾体激素水平往往更高。
与无乳腺病变的女性相比,BBD 患者的循环甾体激素水平往往更高,与非增生性疾病相比,增生性疾病患者的水平更高;这些模式在绝经后女性中更为明显。与健康女性相比,绝经后女性的 BBD 患者 IGF-1 水平较低。